Detection and quantification of residual disease in chronic myelogenous leukemia

A Hochhaus, A Weisser, P La Rosee, M Emig… - Leukemia, 2000 - nature.com
The degree of tumor load reduction after therapy is an important prognostic factor for
patients with CML. Conventional metaphase analysis has been considered to be the 'gold …

Molecular monitoring of residual disease in chronic myelogenous leukemia patients after therapy

R Haas, R Kronenwett, G Sczakiel, A Hochhaus… - … in Hematopoietic Stem …, 1998 - Springer
The degree of tumor load reduction after therapy, which is determined by the degrees of
cytoreduction and cytogenetic response, is an important prognostic factor for patients with …

Minimal residual disease in chronic myeloid leukaemia.

NC Cross - Hematology and cell therapy, 1998 - europepmc.org
The principle aim of residual disease analysis in patients with chronic myeloid leukaemia
(CML) is to gauge patient response to treatment and, in patients after allogeneic BMT, to …

Clinical implications of qualitative and quantitative polymerase chain reaction analysis in the monitoring of patients with chronic myelogenous leukemia. The …

T Lion - Bone marrow transplantation, 1994 - europepmc.org
Recent progress in the development of diagnostic techniques has greatly facilitated the
monitoring of minimal residual disease (MRD) in patients with hematologic neoplasia. The …

Quantitation of minimal residual disease in Philadelphia chromosome positive chronic myeloid leukaemia patients using real‐time quantitative RT‐PCR

Menskin, V De Locht, Schattenberg… - British journal of …, 1998 - Wiley Online Library
We used a recently developed system for real‐time quantitative polymerase chain reaction
(PCR) to determine residual disease in patients with chronic myeloid leukaemia. The …

Detection of BCR-ABL transcripts in chronic myeloid leukemia (CML) using a 'real time'quantitative RT-PCR assay

C Preudhomme, F Revillion, A Merlat, L Hornez… - Leukemia, 1999 - nature.com
Quantitative competitive RT-PCR techniques have been developed to detect BCR-ABL
fusion transcripts in CML but they are hardly reproducible. In this work, we have developed …

[引用][C] Monitoring of residual disease in chronic myelogenous leukemia: Methodological approaches and clinical aspects.

T Lion - Leukemia, 1996 - europepmc.org
Monitoring of residual disease in chronic myelogenous leukemia: methodological approaches
and clinical aspects. - Abstract - Europe PMC Sign in | Create an account https://orcid.org …

Monitoring chronic myeloid leukaemia therapy by real‐time quantitative PCR in blood is a reliable alternative to bone marrow cytogenetics

Branford, Hughes, Rudzki - British journal of haematology, 1999 - Wiley Online Library
We have developed a rapid real‐time quantitative PCR method for measuring BCR‐ABL
mRNA levels in peripheral blood in chronic myeloid leukaemia (CML). The technique was …

Real-time quantification of different types of bcr-abl transcript in chronic myeloid leukemia

M Amabile, B Giannini, N Testoni, V Montefusco… - …, 2001 - haematologica.org
BACKGROUND AND OBJECTIVES: The most common translocation in chronic myeloid
leukemia (CML) t (9; 22)(q34; q22) produces the BCR/ABL fusion gene. We set up and …

Diagnosis and monitoring of chronic myeloid leukemia by qualitative and quantitative RT-PCR

S Branford, T Hughes - Myeloid Leukemia: Methods and Protocols, 2006 - Springer
Real-time quantitative reverse-transcription polymerase chain reaction (RQ-PCR) methods
for the quantitation of BCR-ABL mRNA in the blood of patients with chronic myeloid …